Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review
Open accessThe DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Abstract
Background: GLP-1 analogues are a relatively new class of medications that form the cornerstone of diabetes treatment. They possess invaluable glucose-lowering properties without hypoglycemic effects as well as strong cardioprotective effects. The gut microbiome has become the focus of numerous studies, demonstrating its influence not only on the gut but also on the overall well-being of the entire body. However, the effects of GLP-1 analogs on gut microbiota remain uncertain. Scope of review: Our systematic review (based on PRISMA guidelines) aimed to gather knowledge on the effects of GLP-1 analogue medications on the composition, richness, and abundance of gut microbiota in both animal and human models. Conclusions: Thirty-eight studies were included in this systematic review. GLP-1 analogues have demonstrated a notable impact on the composition, richness, and diversity of gut microbiota. We can conclude, following the obtained research results of our study, that liraglutide promotes the growth of beneficial genera relevant for beneficial metabolic functions. Exenatide and exendin-4 administration showed various effects on the microbiome composition in animal and human studies. In animal models, it increased genera associated with improved metabolism; however, in human models, genera linked to better metabolic functions and escalated inflammation increased. Following dulaglutide administration, increases in Bacteroides, Akkermansia, and Ruminococcus, genera connected to an improved metabolic model, were significant. Finally, varied results were obtained after semaglutide treatment, in which A. muciniphila, known for its positive metabolic functions, increased; however, microbial diversity decreased. Semaglutide treatment provided various results indicating many confounding factors in semaglutide’s impact on the gut microbiota. Results varied due to dissimilarities in the studied populations and the duration of the studies. Further research is essential to confirm these findings and to better recognize their implications for the clinical outcomes of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“G LP-1 receptor agonists (GLP1RAs) increased the intestinal Bacteroidetes to Firmicutes ratio, decreased obesity-related but increased lean-related microbiota phenotypes, and implement bacteria with anti-inflammatory properties (i.e., Akkermansia) [110].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredIn the citing paper
“G LP-1 receptor agonists (GLP1RAs) increased the intestinal Bacteroidetes to Firmicutes ratio, decreased obesity-related but increased lean-related microbiota phenotypes, and implement bacteria with anti-inflammatory properties (i.e., Akkermansia) [110].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [110]
In the citing paper
“G LP-1 receptor agonists (GLP1RAs) increased the intestinal Bacteroidetes to Firmicutes ratio, decreased obesity-related but increased lean-related microbiota phenotypes, and implement bacteria with anti-inflammatory properties (i.e., Akkermansia) [110].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Morris, A. P., Voight, B. F., Teslovich, T. M., Ferreira, T., Segrè, A. V., Steinthorsdottir, V., Strawbridge, R. J., Khan, H., Grallert, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2383 · Cited by 1,912 · cited 1×
“Several groups of factors can be singled out, such as genetic [7], environmental [8], and dietary factors [9].”
Role of gut microbiota in type 2 diabetes pathophysiology
Gurung, M., Li, Z., You, H., Rodrigues, R., Jump, D. B., Morgun, A., & Shulzhenko, N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.051 · Cited by 1,708
Faecalibacterium prausnitzii and human intestinal health
Miquel, S., Martín, R., Rossi, O., Bermúdez-Humarán, L., Chatel, J., Sokol, H., Thomas, M., Wells, J., & Langella, P. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.003 · Cited by 1,228
Amiel, S. A., Aschner, P., Childs, B., Cryer, P. E., de Galan, B. E., Frier, B. M., Gonder-Frederick, L., Heller, S. R., Jones, T., Khunti, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30315-2 · Cited by 526
Introduction and Methodology: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Das, S. R., Gibbons, C. H., et al. (2023) · Diabetes Care · doi:10.2337/dc23-sint · Cited by 366
Remely, M., Aumueller, E., Merold, C., Dworzak, S., Hippe, B., Zanner, J., Pointner, A., Brath, H., & Haslberger, A. G. (2014) · Gene · doi:10.1016/j.gene.2013.11.081 · Cited by 299
Considering gut microbiota in treatment of type 2 diabetes mellitus
Adeshirlarijaney, A., & Gewirtz, A. T. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1717719 · Cited by 174
Cited by
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Tingler, A. M., & Engevik, M. A. (2025) · Infection and Immunity · doi:10.1128/iai.00503-24 · Cited by 66
Fan, Y., Liu, Y., Shao, C., Jiang, C., Wu, L., Xiao, J., & Tang, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125486 · Cited by 62
GLP‐1 agonists and the gut microbiome: A bidirectional relationship
Kamath, S., Chan, N. S. L., & Joyce, P. M. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70487 · Cited by 44
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 36
Probiotics as Antioxidant Strategy for Managing Diabetes Mellitus and Its Complications
Viana, M. D. M., Santos, S. S., Cruz, A. B. O., de Jesus, M. V. A. C., Lauria, P. S. S., Lins, M. P., & Villarreal, C. F. (2025) · Antioxidants · doi:10.3390/antiox14070767 · Cited by 31
History of glucagon-like peptide-1 receptor agonists
Darwish, R., Abu-Sharia, G., & Butler, A. E. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108045 · Cited by 29
Kanbay, M., Al-Shiab, R., Shah, E., Özbek, L., Güldan, M., Ortíz, A., & Fouque, D. P. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf351 · Cited by 28
Barrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A. A. L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00667-3 · Cited by 26
Little, P. J., Offermanns, S., Cho, H., Liu, Z., Yang, P., Su, Q., Wade, H., Yang, W., Kamato, D., Cohen, N. D., et al. (2026) · iNew Medicine · doi:10.1002/inm3.70028 · Cited by 27
Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
Trapanese, V., Dagostino, A., Natale, M. R., Giofrè, F., Vatalaro, C., Melina, M., Cosentino, F., Sergi, S., Imoletti, F., Spagnuolo, R., et al. (2025) · Life · doi:10.3390/life15060843 · Cited by 25
Gut microbiome and obesity care: Bridging dietary, surgical, and pharmacological interventions
Masi, D., Watanabe, M., & Clément, K. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102573 · Cited by 25
Gut-Kidney Axis: Unraveling the Role of the Microbiome in Chronic Kidney Disease
Rusu, M., Ichim, C., Anderco, P., Pălăștea, A.-D., & Boicean, A. (2026) · Biomedicines · doi:10.3390/biomedicines14010109 · Cited by 24
The Role of the Gut Microbiome in Type 2 Diabetes Mellitus
Mashal, R., Al-Muhanna, A., Khader, S., Khudair, A. D., Khudair, A. D., & Butler, A. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311412 · Cited by 18
Gut Microbiota and Metabolic Health: From Dysbiosis to Therapeutics
Pillai, S. S., & Ashraf, A. P. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01851-x · Cited by 18
Anagnostopoulou, L., Ktenopoulos, N., Apostolos, A., Fragoulis, C., Vlachakis, P. K., Karakasis, P., Sagris, Μ., Milaras, N., Drakopoulou, M. I., Synetos, A. G., et al. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70167 · Cited by 15
Ganamurali, N., & Sabarathinam, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01834-y · Cited by 16
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Yan, K., Sun, X., Wang, X., Zheng, J., & Yu, H. (2025) · Nutrients · doi:10.3390/nu17162603 · Cited by 13
Zhang, Y., & Wang, D. D. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2644682 · Cited by 13
Dinkov, B., & Pendicheva-Duhlenska, D. (2026) · Biomedicines · doi:10.3390/biomedicines14040806 · Cited by 13
Chen, Y., Zeng, X., Gong, X., Chen, Y., Zhang, X., & Luo, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149519 · Cited by 11
Wang, Y., Liu, J., Verbeke, K., Gasaly, N., Akkerman, R., & de Vos, P. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100647 · Cited by 11
Kowalska, M. K., El‐Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041886 · Cited by 10
Wang, Y., Lan, B., Zhang, S., Mu, Y., Mi, J., Yu, J., Zhan, Q., Luo, B., Lin, F., Teng, J., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01877-4 · Cited by 8
“In addition, the delay in gastric emptying caused by GLP-1RA and changes in gut microbiota might impact the metabolism and absorption of micronutrients [61, 62].”
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods
Păduraru, D. N., Palcău, A. C., Daniel, I., & Seicaru, R. (2025) · Biomedicines · doi:10.3390/biomedicines13123117 · Cited by 8
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 9
Zhang, K., Dong, Y., Ding, Y., Wang, X., Liu, T., Zhong, W., & Cao, H. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128240 · Cited by 8
Yadav, A., & Melkani, G. C. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-06022-y · Cited by 7
Martínez-Nortes, M. E., Carrascosa, C., Ávila‐Gálvez, M. Á., & Espín, J. C. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.108830 · Cited by 6
Alexander, J. L., Mullish, B. H., Thomas, L., Weersma, R. K., Sokol, H., Roberts, L. A., Edwards, L. A., Emmanuel, A. V., Gerasimidis, K., Hall, L. J., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-338252 · Cited by 6
Obstructive sleep apnea and the gut microbiota – mechanisms and opportunities
Alcock, J. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001211 · Cited by 5
Gultekin, M., Davran, F., YÜKSEL, N. A., Beyazçiçek, Ö., & Demír, Ş. (2025) · Acta Neurologica Belgica · doi:10.1007/s13760-025-02894-w · Cited by 5
HBOT alleviates diet-induced MASH by reprograming gut microbiota and liver metabolism in mice
Chen, L., Xu, S., Zhou, Q., Zhao, T., Zhao, Y., Chen, X., Zhu, W., Ding, J., Zheng, H., Jiang, M., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.05.420 · Cited by 5
Koufakis, T., Patoulias, D., Apostolopoulou, M., Georgianos, P. I., & Popovic, D. S. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2559907 · Cited by 5
Unveiling the gut-kidney dialogue in diabetic kidney disease
Gembillo, G., Soraci, L., & Visconti, L. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i11.112440 · Cited by 5
Dumitru, C. N., Dumitru, A. O., Goroftei, L., Niculet, E., Ignat, M. D., Baroiu, L., Nechita, A., & Balan, G. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060651 · Cited by 4
Г.Т., Т., Zholdassova, M., Novosolova, N., Malm, T., Giniatullin, R. A., & Kustubayeva, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010369 · Cited by 5
Saghafi, S., Yaghoubi, M. A., Safarpour, H., Raeisi, H., & Mousavi, Z. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118948 · Cited by 4
Barros, H. D. D. F. Q., Casagrande, B. P., Araújo, D. D., Mutran, T. A. J., Telles, M. M., Estadella, D., & Pisani, L. P. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10038-5 · Cited by 4
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 4
Dinkov, B. (2026) · Biomedicines · doi:10.3390/biomedicines14061235 · Cited by 4
Motte, L. R. D. L., Carreras, F., & Drago, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1858420 · Cited by 4
Hutchinson, N. T., Pang, Z., Chimezie, C. I., Hamp, B., Haley, A. E., & Li, J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115160 · Cited by 4
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 4
DIFFERENCES IN GUT MICROBIOTA MODULATION BY SEMAGLUTIDE, LIRAGLUTIDE AND TIRZEPATIDE
Nowakowska, J., Krawczyk, M., Komasara, P., Szwarc, T., Kałwik, M., Mikołajczak, P., Płusa, A., Brożyna, D. W., Sałapski, B. A., & Żyła, D. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3563 · Cited by 3
Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes: A Real-World Data Cohort Study
Chuang, C.-H., Tsai, P., Kao, S.-W., Wang, Y., & Yeh, C. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.072875 · Cited by 3
Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice
Oh, E. Y., Suh, S. H., Byeon, S., Lee, J., Lee, Y.-H., & Choi, S.-K. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119042 · Cited by 3
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
Semiz, S. (2025) · Health Sciences Review · doi:10.1016/j.hsr.2025.100244 · Cited by 2
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Abdelaziz, A. M. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116628 · Cited by 2
Myśliwczyk, D., Gofron, K. K., Wasilewski, A., Myśliwiec, M., & Wasilewska, E. (2026) · Nutrients · doi:10.3390/nu18111662 · Cited by 2
Self-citationTroshina, E. A., Antsiferov, M. B., As, A., Bakulin, I. G., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2026) · Problems of Endocrinology · doi:10.14341/probl13784 · Cited by 2
Gut Microbiota and Metabolic Syndrome: A Narrative Review
Kotsiri, I., Prokou, M., Domazinaki, C.-M., Papadakaki, E., & Magiorkinis, E. (2026) · Biology · doi:10.3390/biology15141115 · Cited by 2
The Postprandial Chronobiome in Interorgan Glucose Homeostasis
Božić, J., Šantić, R., & Kumrić, M. (2026) · Comprehensive physiology · doi:10.1002/cph4.70236 · Cited by 2
Effects of liraglutide on gut bacterial community dynamics
Bull, J., Durham, P. L., & Mirza, B. S. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00343-26 · Cited by 2
Effects of GLP ‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review
Dantas, R. S., Santos, L. V. S., de Oliveira, A. G. C., Barreto, M. D. S., Silva, D. M. R. R., Moura, P. H. M., Silva, E. E. D., Santos, R. S., Santana, L. A. D. M., Gopalsamy, R. G., et al. (2026) · FEBS Journal · doi:10.1111/febs.70656 · Cited by 3
de Waal, J. R., Nieuwdorp, M., & Gerdes, V. E. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1680182 · Cited by 1
Gao, L., Shao, Q., Zhuo, X., Xu, Y., & Zhang, Y. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1783385 · Cited by 1
Szkamruk, Z., Cielecka, J., Walędziak, M., & Różańska-Walędziak, A. M. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00596-0 · Cited by 1
Oriquat, G., Abdulsahib, W. K., Mustafa, W. W., Gajjar, T. B., Hanumanthayya, M., Shukla, S. K., Panigrahi, R., Bainsal, N., & Khaitova, S. (2026) · PROTOPLASMA · doi:10.1007/s00709-026-02235-5 · Cited by 1
Tirzepatide and the gut microbiota–obesity axis: metabolic mechanisms and therapeutic perspectives
Cadena-Ullauri, S., Paredes, A. S. C., Guamán-Herrera, L., Imbaquingo-Espinales, J., Ruiz‐Pozo, V. A., Tamayo‐Trujillo, R., Guevara‐Ramírez, P., Paz‐Cruz, E., & Zambrano, A. K. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1901528 · Cited by 1
Oral Adverse Effects of Semaglutide Therapy: A Narrative Review
Al-Zawawi, A. S. (2026) · Journal of International Society of Preventive and Community Dentistry · doi:10.4103/jispcd.jispcd_5_26 · Cited by 1
Wang, Z., Wang, X., Zheng, W., Lu, W., Hao, L., Wang, X., Huang, C., Wang, R. L., Hu, Y., Wang, Z., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158600 · Cited by 1
Pharmacomicrobiomics in metabolic syndrome and type 2 diabetes: the microbiome–drug–host triad
Strilić, D., Stanimirov, B., Pavlović, N., Lazarević, S., Mikov, M., Stanivukovic, T., & Đanić, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1831882 · Cited by 1
Heng, Y., & Qiuming, Y. (2026) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2026.103032
Carvalho, P. V., Carvalho, M. D. G. D. S., & da Silva, M. M. (2025) · International Journal of Molecular Biology Open Access · doi:10.15406/ijmboa.2025.08.00198
Zarówna, K., Pura, W., Mazur, J., Marciniak, J., Kosowski, M., Matecka, D., Śliwiński, W., & Chołuj, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4791
Endocrine cells of the gastroenteropancreatic system in Testudines A brief review
de Sousa, D. F., Guerra, L. D. S., Branco, E. R., Ferreira, P. G., & de Lima, A. R. (2026) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2026.114934
Zanoni, A., Facchin, S., Mari, V., Bertin, L., & Savarino, E. V. (2026) · Pharmaceuticals · doi:10.3390/ph19050705
Reis, L. F., Yvamoto, E. Y., de Jesus, L. B. F., Saraiva, H. P., & Oliveira, É. S. (2026) · Revista fisio&terapia. · doi:10.69849/7wmx9h50
Kowalczyk, A., Fąfara, M., Jeczkało, M., Kosiorowska, M., Lasoń, J., Makulska, M., Płachta, W., Sęk, W., Sieradzka, A., & Wegenko, C. M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5787
Saka, W. A., Oyedokun, P. A., Alade, T. A.-M., Oyeleke, B. T., Oyelaran, A. O., Oyedokun, M. D., Irozuoke, C. A., Olayemi, O. M., Oladepo, S., & Ndako, J. A. (2026) · Antonie van Leeuwenhoek · doi:10.1007/s10482-026-02349-z
McGuane, C., Farhadhar, N., Sharieff, K. A., Petrosky, S. N., & Alabasi, K. (2026) · Cureus · doi:10.7759/cureus.109731
GLP-1 receptor agonists in neuroinflammation: a novel therapeutic target?
Silva, P. B. P., de Castro, R. M., dos Santos, J. P., Gouveia, H. J. C. B., & Toscano, A. E. (2026) · Nutritional Neuroscience · doi:10.1080/1028415x.2026.2680999
Влияние бариатрической хирургии на кишечную микробиоту: систематический обзор литературы
Завьялова, Т. А., Strokova, M. I., & Петунина, Н. А. (2026) · Фармакология & Фармакотерапия · doi:10.46393/27132129_2026_2_93-104
Longitudinal analysis of short-chain fatty acid profiles in stool of sleeve gastrectomy patients
Lange, O., Budny, A., Janczy, A., Wilczyński, M., Szymański, M., Proczko-Stepaniak, M., Śledziński, T., & Mika, A. (2026) · Nutrition and Diabetes · doi:10.1038/s41387-026-00441-x
Amoyel, M., Bado, A., Poghosyan, T., Roy, T. L., & Gall, M. L. (2026) · npj Biofilms and Microbiomes · doi:10.1038/s41522-026-01058-9
КИШКОВА МІКРОБІОТА ТА ЇЇ РОЛЬ У РОЗВИТКУ ЕНДОКРИННИХ ЗАХВОРЮВАНЬ: ЕНДОКРИННО-ФАРМАКОЛОГІЧНІ АСПЕКТИ
Кравчун, Н. А., Дунаєва, І., Кравчун, П. П., Кривошапка, О., Шаповал, О. М., Pautina, O. I., & Doroshenko, O. M. (2026) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2026.2.06
Wiciński, M., Kuźmiński, O., Konopacka, K., Kowalka, W., Słomko, W., & Gierach, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135069
Gastrointestinal and Extra-Metabolic Effects of GLP-1-Based Therapies: A Narrative Review
Geetha, S. S., Abbas, S. M. N. E., Saadi, A. R., Nair, S. A., & Elhassan, O. A. A. (2026) · JUNIOR RESEARCHERS · doi:10.52340/jr.2026.04.02.06
Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities
Gökcen, B. B., Atabılen, B., Güneş, B. D., Dazıroğlu, M. E. Ç., Özer, Ş. D., Biten, A. A., Pagano, E., Nanì, M. F., Romano, B., Ağagündüz, D., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1836931
The role of gut microbiota in obesity and its potential therapeutic treatments - A Literature Review
Stróżyk, K., Bąk, M., Mehal, K., Zawadziński, W., Szamocka, K., Pielich, W. M., Balicka-Dworczak, N., Kuliński, T., & Siusta, N. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.94.73088
Ahmed, A. K. K., Rodini, S., Alrubyea, F., & Akl, M. M. (2026) · Problems of Endocrinology · doi:10.14341/probl13660
Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications
Fan, H., Wu, J., Shen, Y., & Zheng, W. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s613343
Juszczyk, A. K., Pietrajtis, S. J., Sałapski, B. A., Brożyna, D. W., Kubicki, M., Grębosz, D., Piec, J., Komornik, W., Łebek, M., & Lis, K. (2026) · Quality in Sport · doi:10.12775/qs.2026.67.74171
ORAL MANIFESTATIONS ASSOCIATED WITH THE USE OF GLP-1 RECEPTOR AGONISTS
do Couto, A. K. B., Lambertini, G. J. G., Filho, G. M., da Cruz, K. M., de Toledo, L. S. C., & Damião, R. E. V. (2026) · Seven Editora eBooks · doi:10.56238/sevened2026.032-001
Nesterova, E. Y., Gladkikh, M. I., Burakova, I. Y., Korneeva, O. S., Dmitrievna, M. P., & Syromyatnikov, M. (2026) · Diabetology · doi:10.3390/diabetology7080153
Hammad, M. A. M., Perelmuter, S., Furlan, V. A., Nakamura, H., Rubin, R. S., & Yih, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10580243/v1
Monteiro, T. M., Carvalho, M. A. C., ARAÚJO, L. L. D., dos Santos, H. S. C., de Lima, S. Y. V., de Queiroz, B. F. S., da Costa, L. T., de Brito, A. N. M., Cardoso, H. D. S. F., Cardoso, V. E. D. S. C., et al. (2026) · Revista Tópicos · doi:10.70773/revistatopicos/787496864
Makiel, K., & Suder, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176671
Kalafati, I. P., Krongauz, D. L., Bosco, A., Noto, A., Piras, C., Kafyra, M., Dessì, A., Mauri, M., Atzori, L., Weinberger, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70220
The Microbiota–Gut–Brain Axis in Obesity: Inflammation, Appetite Dysregulation, and Feeding Behavior
Sandoval-Valenzuela, C., & Pacheco, R. (2026) · Nutrients · doi:10.3390/nu18203409
Burtowicz, J., Kossmann, M., Szalewska, L., Abdulgater, A., Osuch-Tomaszewska, P., Urowska, W., Łysiak, J., & Kazubek-Fuksiewicz, I. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5930
Zhang, S., Wei, H., Wang, Q., Zhang, M., Wan, G., Wang, J., Leng, J., Li, J., Chen, D.-L., Huang, B., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01535-0
Letter to the Editor: The Gut Microbiome–Endocrine Axis in Obesity: Mechanisms and Therapeutics
Su, J. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70772
Metadata
- Authors
- Gofron, K. K., Wasilewski, A., & Małgorzewicz, S.
- Affiliations
- Gdańsk Medical University (PL)
- Wroclaw Medical University (PL)
- Corresponding author
- Gofron, Krzysztof Ksawery
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2025-04-09
- Volume
- 17
- Issue
- 8
- Pages
- 1303
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12029897
- OpenAlex
- W4409301238
- Cited by
- 90
- References
- 66
- Citations by year
- 2026: 64 · 2025: 26
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Medical University of Gdańsk (NIP 584-09-55-985)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Keywords
- GLP-1 receptor agonists, gut microbiota, liraglutide, exenatide, exendin-4, dulaglutide, semaglutide, Akkermansia muciniphila, Bacteroides, Ruminococcus, microbial diversity, inflammation, diabetes treatment
- MeSH terms
- Gastrointestinal Microbiome, Liraglutide, Exenatide, Animals, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

![Figure 2 Risk of bias assessment [15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52].](https://figures.cochat.ai/paper-figures/a47f218f4acf4e53bb8f9b0338ca214a/effects-of-glp-1-analogues-and-agonists-on-the-gut-microbiota-a-systematic-figure-2.jpg)